News
REPL: Awaiting April 10 FDA decision on RP1, with strong clinical, commercial, and pipeline momentum
1+ hour, 12+ min ago (90+ words) REPL: Awaiting April 10 FDA decision on RP1, with strong clinical, commercial, and pipeline momentum'TradingView REPL: Awaiting April 10 FDA decision on RP1, with strong clinical, commercial, and pipeline momentum The company is advancing its HSV-based oncolytic immunotherapy platform, with RP1 awaiting an FDA decision…...
DNTH: Early Phase 3 success and robust cash reserves drive late-stage autoimmune pipeline progress
8+ hour, 11+ min ago (74+ words) DNTH: Early Phase 3 success and robust cash reserves drive late-stage autoimmune pipeline progress'TradingView DNTH: Early Phase 3 success and robust cash reserves drive late-stage autoimmune pipeline progress Early GO decision in Phase 3 CIDP trial and strong cash position highlight progress in…...
SGMT: Phase II MASH and acne studies set for late 2024, leveraging strong FASN inhibitor data
1+ hour, 55+ min ago (84+ words) SGMT: Phase II MASH and acne studies set for late 2024, leveraging strong FASN inhibitor data'TradingView FASN inhibition is being advanced for MASH and acne, with Denifanstat as the lead candidate and a combination with Resmetirom targeting F4 cirrhotic MASH. Phase II…...
RCUS: Casdatifan delivers higher efficacy and durable responses in RCC, with strong upcoming trial data
3+ hour, 31+ min ago (71+ words) RCUS: Casdatifan delivers higher efficacy and durable responses in RCC, with strong upcoming trial data'TradingView Casdatifan shows superior efficacy and durability over belzutifan in RCC, with higher response rates, longer PFS, and robust biomarker correlation. Safety is comparable, and ongoing…...
ZNTL: Azenosertib shows >30% response in PROC, with pivotal trials and expansion strategies progressing
2+ hour, 25+ min ago (76+ words) ZNTL: Azenosertib shows >30% response in PROC, with pivotal trials and expansion strategies progressing'TradingView ZNTL: Azenosertib shows >30% response in PROC, with pivotal trials and expansion strategies progressing Azenosertib is advancing in platinum-resistant ovarian cancer, with DENALI Part 2 and the ASPENOVA phase…...
CVS: Integrated pharmacy, PBM, and digital platforms drive consumer-focused, affordable healthcare
6+ hour, 16+ min ago (62+ words) CVS: Integrated pharmacy, PBM, and digital platforms drive consumer-focused, affordable healthcare'TradingView CVS: Integrated pharmacy, PBM, and digital platforms drive consumer-focused, affordable healthcare Leadership is integrating pharmacy, PBM, and care delivery to create a seamless consumer experience, leveraging technology, acquisitions, and…...
KYTX: Pivotal miv-cel data in SPS shows disease reversal, with BLA filing and launch planned this year
3+ hour, 40+ min ago (76+ words) KYTX: Pivotal miv-cel data in SPS shows disease reversal, with BLA filing and launch planned this year'TradingView Transformative pivotal data for miv-cel in stiff person syndrome showed disease reversal and strong safety, with BLA filing and launch targeted for this…...
Xenon surges as epilepsy drug delivers strong late‑stage results
8+ hour, 42+ min ago (21+ words) Xenon Pharma's epilepsy drug meets main goal in late-stage trial'TradingView Xenon surges as epilepsy drug delivers strong late'stage results...
ALMS: Envudeucitinib delivers leading efficacy in psoriasis, with broad TYK2 franchise expansion ahead
4+ hour, 17+ min ago (83+ words) ALMS: Envudeucitinib delivers leading efficacy in psoriasis, with broad TYK2 franchise expansion ahead'TradingView ALMS: Envudeucitinib delivers leading efficacy in psoriasis, with broad TYK2 franchise expansion ahead Envudeucitinib showed top-tier efficacy and rapid onset in phase III psoriasis trials, with long-term data and…...
Healthcare Jobs Drop, UnitedHealth Stock Slips: Opportunity or Risk?
5+ hour, 6+ min ago (620+ words) Healthcare Hiring Slowdown Adds to Sector Concerns The national unemployment rate ticked up to 4.4% compared with 4.3% recorded in January. For health insurers, these dynamics can ultimately influence claims patterns, provider pricing and overall cost structures. Market Rotation and Stock Weakness…...